Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelmastobart (hSTC810) monotherapy in advanced solid tumors
NCT05231746Phase 1Completed
- Sponsor
- STCube
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of nelmastobart in solid tumor (advanced stage), sponsored by STCube. Primary endpoints: Incidence of Dose-Limiting Toxicities at 4 weeks and Incidence of Adverse Events, Serious Adverse Events, and Laboratory Abnormalities. Started Apr 2022; status: completed.
02
Drugs
nelmastobart
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05231746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05231746.